atosiban

Also Known As:

(Mpa(1),D-Tyr(Et)2,Thr(4),Orn(8))oxytocin; (Mpa(1)-D-Tyr(Et)(2)-Thr(4)-Orn(8))-oxytocin; 1-deamino-2-Tyr(OEt)-4-Thr-8-Orn-oxytocin; ORF 22164; ORF-22164; RWJ 22164; RWJ-22164; oxytocin, 1-deamino-(O-Et-Tyr)(2)-Thr(4)-Orn(8)-; oxytocin, 1-deamino-O-ethyltyrosyl(2)-threonyl(4)-ornithine(8)-

Networked: 156 relevant articles (22 outcomes, 41 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Alizadeh, Ali Mohammad: 5 articles (01/2019 - 07/2010)
2.	Khori, Vahid: 5 articles (01/2019 - 07/2010)
3.	Mol, Ben W: 4 articles (07/2022 - 05/2016)
4.	Hadar, Eran: 4 articles (08/2021 - 06/2011)
5.	Oudijk, M A: 4 articles (12/2020 - 06/2018)
6.	Kok, Marjolein: 4 articles (11/2019 - 05/2016)
7.	Lamont, Ronald F: 4 articles (04/2010 - 01/2003)
8.	Oudijk, Martijn A: 3 articles (07/2022 - 05/2016)
9.	Mol, B W: 3 articles (12/2020 - 06/2018)
10.	Schuit, Ewoud: 3 articles (11/2019 - 05/2016)

Related Diseases

1.	Premature Obstetric Labor (Premature Labor) 01/01/1998 - "Goodwin et al compared the effect of Atosiban to placebo in threatening preterm labor and the antagonist was in this trial significantly more effective than placebo in reducing the frequency of contractions (55% vs. 23%, p < 0.001). " 09/01/2020 - "To compare the efficacy of atosiban with conventional treatment of the threatened preterm labor. " 01/01/2016 - "Evaluation of the efficacy of atosiban in pregnant women with threatened preterm labor associated with assisted reproductive technology." 01/01/2007 - "To compare the efficacy of atosiban with usual management of threatened preterm labor. " 01/01/2016 - "The present study aimed to investigate the effectiveness of atosiban in treating women with threatened preterm labor who had become pregnant through assisted reproductive technology (ART) and the corresponding pregnancy outcomes. "
2.	Premature Birth (Birth, Premature) 12/01/2004 - "Atosiban is a newer agent, which appears to be effective in delaying preterm birth with a favourable maternal safety profile, but there are persisting concerns about the lack of impact on perinatal mortality and morbidity. " 10/21/2022 - "Correction: Study protocol for a randomised trial for atosiban versus placebo in threatened preterm birth: the APOSTEL 8 study." 11/26/2019 - "Study protocol for a randomised trial for atosiban versus placebo in threatened preterm birth: the APOSTEL 8 study." 01/01/2007 - "These findings support the use of atosiban to delay preterm birth and are consistent with previously conducted, randomized, controlled trials. " 01/01/2023 - "However, subgroup analysis demonstrated significantly higher preterm birth rates in the control group compared with the atosiban group (0 versus 3.0%, P = 0.024) in the natural FET cycles. "
3.	Endometriosis 08/01/2016 - "Atosiban treatment before ET in endometriosis is effective in the priming of the uterus, suitable for embryo implantation. " 08/01/2016 - "This is the first study to evaluate the effect of atosiban treatment in patients with endometriosis. " 08/01/2016 - "Administration of atosiban in patients with endometriosis undergoing frozen-thawed embryo transfer: a prospective, randomized study." 08/01/2016 - "In the endometriosis treatment group, a single bolus (6.75 mg, 0.9 mL per vial) of atosiban was administrated before ET. " 08/01/2016 - "One hundred twenty women with endometriosis undergoing frozen-thawed embryo transfer were randomly allocated into the atosiban treatment and the control groups. "
4.	Tachycardia (Tachyarrhythmias) 08/05/2021 - "Treatment with atosiban (a Gi biased agonist) inhibited restraint-evoked tachycardia without affecting blood pressure. " 10/01/2009 - "Fetal tachycardia was lower in the atosiban group (2% vs. 22%). " 07/01/2006 - "We conclude that atosiban is associated with a significantly lower incidence of maternal tachycardia and improved neonatal outcome compared with ritodrine." 06/01/2009 - "The present study showed similar effectiveness between atosiban and ritodrine, while tachycardia occurred more frequently in women treated with ritodrine. " 06/01/2009 - "There were no serious adverse events, but maternal cardiovascular adverse events, particularly tachycardia, occurred significantly more in women treated with ritodrine (0% atosiban vs. 18.18% ritodrine, p < 0.05). "
5.	Neoplasms (Cancer) 01/01/2022 - "Moreover, 5-Fu induced GATA3 in MSS CRC cells and tumors, which were eradicated by atosiban. " 01/01/2018 - "Thirty-two BALB/c female mice were equally divided into four groups to study the effects of OT and atosiban (ATO) (an oxytocin receptor antagonist) on the mammary tumor growth. "

Related Drugs and Biologics

1.	Ritodrine (Yutopar)
2.	Nifedipine (Adalat)
3.	Oxytocin (Pitocin)
4.	Tocolytic Agents (Tocolytics)
5.	Oxytocin Receptors (Oxytocin Receptor)
6.	Magnesium
7.	Terbutaline (Brethaire)
8.	Peptides (Polypeptides)
9.	Fibronectins (Fibronectin)
10.	Nitric Oxide Synthase (NO Synthase)

Related Therapies and Procedures

1.	Tocolysis
2.	Therapeutics
3.	Intravenous Administration
4.	Resuscitation
5.	Intravenous Infusions